The best choice to integrate molecular diagnostics into your practice.

GeneSite Lab
Advanced Molecular Diagnostics, LLC
222 Route 59 - Suite 20, Suffern - NY - 10901
Tel: 866-GEN-AMD, Fax: 845-357-5207
Email: Info@GeneSiteLab.com
Website: GeneSiteLab.com

GeneSite
The Future Today

GeneSite
The Future Today

The link between faculty research and your private practice.

New York | New Jersey | Vermont | Pennsylvania | Florida | Puerto Rico

GENESITE, THE BEST CHOICE TO INTEGRATE MOLECULAR DIAGNOSTICS INTO YOUR PRACTICE.

Our goal

To improve the accessibility, cost-effectiveness and quality of genetic diagnostics on a global scale.

GeneSite Provides the medical communities with timely and accurate molecular testing, with expert interpretation and clinical consultation.

Our Values

- Commit to Service Excellence
- To willingly serve all those with whom we deal; with unsurpassed excellence.
- Treat each other with Respect and Honesty
- To grow a workplace where trust, team spirit, and equity are an integral part of everything we do.
- Demonstrate Responsibility and Accountability
- To set an example, to take ownership of each situation to the best of our ability, and to seek help when needed.
- Be Enthusiastic about Continuous Improvement
- To never be complacent, to recognise limitations and opportunities for ourselves and processes and to learn through these.
- Maintain Confidentiality
- To keep all information pertaining to patients, as well as professional and commercial issues, in strict confidence.

GeneSite
The Future Today

Experienced Leadership

Medical Director: Bader M Pedemonte, MD

Scientific Director: Daniel Cohen, MD

Chief Medical Officer: Seshamma T Reddy, MD, PhD

CEO and President : Dr Pablo J Umansky

Chief Financial Officer: Dr Amalia Abut

Our continual investment in quality ensures that GeneSite exceeds the expectations of its customers.

About
OUR MISSION

As a leader company in Personalized Medicine, we assist you in the screening, diagnosis, classification of cancer patients, and the optimization of drug therapy.

GenSite , a CLIA-certified and CAP-accredited molecular laboratory, provides the highest quality molecular testing services to medical practitioners. Our highly experienced pathologists and molecular geneticists are leaders in their field with specialist knowledge and expertise. They provide current, informed and practical advice to assist with interpretation of results. Our pathologists are members of hospital boards and health policy committees and provide a renowned and comprehensive service to thousand patients each year, reaching private and public hospital beds, specialists and general practitioners throughout United States and worldwide.

Doctors face an ever-expanding variety of genetic tests that could influence how they care for patients. Since the Human Genome Project was completed in 2003, the introduction of new genetic tests has far outpaced the ability of health practitioners – who typically have little training in genetics – to figure out what to do with them.

GeneSite translates scientific discoveries into customized and more effective treatments for your patients. We can help to predict disease risk, or to determine how patients might respond to certain treatments.

The technologies that come under the umbrella of molecular diagnostics at GeneSite Laboratories include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microchips. The same technologies that are improving the discovery of therapeutic molecules for cancer, are been used by GeneSite to assist in the screening, diagnosis, classification of cancer patients, and the optimization of drug therapy. GeneSite is at the core of customized healthcare enabling providers to match drugs to patients based on their genetic profiles, to identify which health conditions an individual is susceptible to, and to determine how a given patient will respond to a particular therapy.

FRASES SUELTAS

"GLOBAL-MUTATIONS-ID-CARD"
THE PLUS VALUE SERVICE OF
GENESITE LABORATORIES

Global Mutations-ID-Card;
the gene-expression signature attached to the unique biologic phenotype of cancer patients.

GeneSite
The Future Today



GeneSite
The Future Today

GeneSite Preventest

We offer our Preventest Panels to individuals with a personal or family history suggestive of a genetic cancer susceptibility.
Our results have accepted clinical validity and they are accompanied by a pre- and post-test genetic counseling with a certified genetic counselor, which discusses the possible risks and benefits of early detection and prevention modalities.

- Breast Cancer (CHEK2, PALB2)
- Breast Cancer, Lobular (CDH1)
- Colon Cancer, Signet Ring (CDH1)
- Colorectal cancer(APC, MUTYH)
- Fanconi Anemia (CDH1)
- Hereditary Nonpolyposis Colorectal Cancer (MLH1, MSH2, MSH6, MSI, IHC)
- Hereditary Nonpolyposis Colorectal Cancer (EPCAM)
- Leukemias and Lymphomas: T-PLL, B-CLL, Mantle Cell Lymphomas (ATM)
- Li-Fraumeni Syndrome (p53, CHEK2)
- Li-Fraumeni-like Syndrome (p53, CHEK2)
- Pancreatic Cancer (PALB2)
- Peutz-Jeghers syndrome (STK11)
- PTEN hamartoma tumor syndrome (PTEN)
- Prostate Cancer (CHEK2)

FRASES SUELTAS

"GLOBAL-MUTATIONS-ID-CARD" ...
THE PLUS VALUE SERVICE OF
GENESITE LABORATORIES

Global Mutations-ID-Card;
the gene-expression signature
attached to the unique biologic
phenotype of cancer patients.

GeneSite
The Future Today

Key points about our services

GeneSite's technology is based on next-generation sequencing; a method of sequencing large amount of DNA in a very short period of time.

Our tests are optimized and extensively validated, with an average turnaround time of 24-48 hs.

We require very small amount of tissue from routine clinical pathological specimens, such as formalin-fixed paraffin embedded tissues, cells suspensions, core needle biopsies or fine needle aspirates.

Any molecular patterns linked to human oncogenesis- point mutations, insertions, deletions, genomic rearrangements, copy number alterations and methylation- are detected with unprecedented sensitivity and specificity by semiconductor sequencing chips that surpass the sensitivity levels achieved with microarrays.

Our sequencing technology generates comprehensive and quantitative data in a fast and cost-effective way, starting with small input amounts of nucleic acids.

Our accessible and actionable reports result from the characterization of hundreds of mutation analysis across multiple key cancer genes, providing doctors with electronic and secure access to patient results from anywhere. All data is HIPAA-Compliant for security.

GeneSite
The Future Today

GeneSite
The Future Today

Genetic diseases diagnostic and inherited mutations analysis

GeneSite offers next-generation sequencing technologies to analyze more than 300 genes and 10,000 amplicons implicated in several diseases, like deafness, cardiovascular diseases, inborn errors of metabolism, neuromuscular diseases, retinitis pigmentosa, Parkinson syndrome, Charcot Marie Tooth disease, mental retardation, etc.

Our genetic testing are reported by licensed and certified health professionals. They gather relevant data and interpret it for patients, providing in-depth support, and facilitating thoroughly informed, autonomous decisions.

GeneSite
The Future Today

GeneSite
The Future Today



TOP MOLECULAR PCR MENU

LUNG CANCER
COLORECTAL CANCER
GASTRIC CANCER
MELANOMA
BRAIN TUMOR
OTHER

GENESITE MOLECULAR PORTFOLIO

GM-ID-CARD
GENESITE PREVENTEST
GENETIC DISEASES-INHERITED MUTATIONS

GeneSite
The Future Today

GeneSite
The Future Today